iVAC-HNSCC01: Two-arm, placebo-controlled, double-blinded, randomized Phase II study to evaluate efficacy and safety of personalized multi-peptide vaccination in combination with Pembrolizumab in patients with unresectable recurrent, or metastatic head and neck squamous cell carcinoma

• Applicant: Professorin Dr. Juliane Walz
• Subject Area: Otolaryngology, Phoniatrics and Audiology ; Immunology
• Term: since 2026
• Project identifier: Deutsche Forschungsgemeinschaft (DFG) - Project number 569928171

No abstract available

• DFG Programme: Clinical Trials
• Co-Investigator: Dr. Sarah M. Schröder